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982Inﬂuence of foot ulceration on cause-speciﬁc
mortality in patients with diabetes mellitus
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Keith G. Jones, MD,a Natasha Patel, MBChB,b Matthew M. Thompson, MD,a and
Robert J. Hinchliffe, MD,a London, United Kingdom
Objective: The purpose of this study was to assess the odds of all-cause mortality in individuals with diabetic foot
ulceration (DFU) compared with those with diabetes and no history of DFU. In addition, we sought to determine the
strength of association of DFU with cardiovascular and nonvascular mortality.
Methods:We obtained data for a cohort of patients who attended a secondary care diabetic foot clinic or a general diabetes
clinic between 2009 and 2010. A clinic cohort of patients with diabetes and no history of DFU provided a control group.
Cause-speciﬁc mortality was recorded during a median follow-up duration of 3.6 years (interquartile range, 3.3-
4.2 years). The association between DFU and all-cause mortality was evaluated by Cox regression. The association
between DFU and cardiovascular mortality was determined by competing risk modeling.
Results:We recorded 145 events of all-cause mortality and 27 events of cardiovascular mortality among 869 patients with
diabetes. After adjustment for potential confounders, DFU was associated with both cardiovascular disease (hazard ratio,
2.53; 95% conﬁdence interval, 0.98-6.49; P [ .05) and all-cause mortality (hazard ratio, 3.98; 95% conﬁdence interval,
2.55-6.21; P < .001). The proportion of deaths attributable to cardiovascular disease was similar between the groups
(18% with diabetes only and 19% with DFU; P [ .91).
Conclusions: DFU is associated with premature death from vascular and nonvascular causes. (J Vasc Surg 2014;60:982-6.)Diabetes mellitus (DM) is an established risk factor for
several causes of death, including ischemic heart disease,
stroke, renal disease, infectious diseases, and several can-
cers.1,2 Estimates based on analysis of 123,205 deaths
among 820,000 people suggest an adjusted hazard ratio
(HR) of 1.80 (95% conﬁdence interval [CI], 1.71-1.90)
for death from any cause compared with persons without
diabetes.1 Evidence is also emerging that diabetic foot
ulceration (DFU) carries an even greater risk of premature
death. A meta-analysis of 3619 deaths among individuals
with DM and those with a history of DFU reported a
higher risk of all-cause mortality in patients with DFU
(relative risk, 1.89; 95% CI, 1.60-2.23).3 This excess
risk was attributable, in part, to a greater burden of cardio-
vascular disease (CVD), with greater event rates for both
fatal cerebrovascular accident (ﬁve vs four per 1000
person-years) and fatal myocardial infarction (17 vs 12
per 1000 person-years) in the DFU group compared
with the DM group. Importantly, this meta-analysis was
limited by a lack of individual patient data to establish
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ship between DFU and cause-speciﬁc mortality, including
the strength of association between DFU and nonvascular
causes of death. We hypothesized that DFU might signal
an increased risk of cardiovascular mortality among patients
with diabetes, accounting in part for an excess risk of death
from all causes. The purpose of this study was to evaluate
differences in overall mortality and mode of death among
adults with diabetes, with and without a history of foot
ulceration. Speciﬁcally, we sought to assess the following:
(1) the odds of all-cause mortality in individuals with
DFU compared with those with diabetes and no history
of DFU; and (2) the relative contribution of CVD and
nonvascular deaths to any excess odds in overall mortality.
METHODS
Patients. A single-center cohort of all patients
attending a diabetic foot clinic between January 2009 and
December 2010 was studied retrospectively. In the United
Kingdom, patients with DFU are referred from the com-
munity into secondary care foot clinics and managed
according to current guidelines provided by the National
Institute for Health and Care Excellence,4 as part of an
established care pathway. In the present study, patients
were managed by a multidisciplinary team involving
specialist diabetes physicians, microbiologists, vascular
surgeons, and podiatrists. Patients are typically reviewed in
the foot clinic weekly until complete healing is achieved.
Our control group consisted of patients with DM
attending a general diabetes clinic during the same period.
Data were extracted for consecutive patients attending the
general diabetes clinic until the number of patients in the
control group matched those in the DFU group. Patients
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biannually to optimize blood glucose control, to evaluate
and manage the development of complications of diabetes,
and to institute appropriate CVD risk management. Car-
diovascular risk in patients from both clinic populations was
managed according to current guidelines at the time of the
clinic visit.5,6 Demographic data, cardiovascular risk factors,
and prescribing information were recorded from clinic
letters, case notes, and electronic hospital records.
Inclusion criteria speciﬁed patients $18 years of age
with a conﬁrmed diagnosis of diabetes, veriﬁed by diag-
nostic tests, hypoglycemic therapy, or medical records re-
view. Diagnostic criteria for DM were consistent with the
American Diabetes Association deﬁnition: fasting plasma
glucose concentration $126 mg/dL or use of hypoglyce-
mic therapy.7 Patients included in the foot ulcer group
had active ulceration at baseline; however, this did not
necessarily represent the ﬁrst diagnosis of DFU. Patients
in the DM group with a documented history of foot ulcer-
ation were excluded from all analyses. A foot ulcer was
deﬁned as a full-thickness skin defect that was observed
during three consecutive visits to the multidisciplinary
foot clinic. Ischemic heart disease was deﬁned by previous
myocardial infarction or unstable angina and coronary
revascularization by a previous coronary angioplasty or cor-
onary artery bypass grafting procedure. Stroke was deﬁned
by a documented history of ischemic stroke (not including
transient ischemic attack). Peripheral arterial disease (PAD)
was deﬁned by a history of intermittent claudication or rest
pain, the absence of two foot pulses, or an abnormal ankle-
brachial pressure index (< or > 0.9 to 1.1) or conﬁrmed by
duplex ultrasound, computed tomography angiography, or
angiography. Congestive cardiac failure was deﬁned by left
ventricular systolic dysfunction on echocardiography or
documented history of heart failure.
Cause of death. Cause of death was ascertained by
review of death certiﬁcates and veriﬁed against case notes
and electronic hospital records. Primary care physicians
were contacted by phone if there was doubt about the
cause of death when deaths occurred in the community.
DFU-related deaths were deﬁned as those directly related
to the foot ulcer (eg, sepsis secondary to DFU) and deaths
resulting from complications after admission to the hospital
or within 30 days of admission to the hospital for DFU (eg,
organ failure resulting from sepsis, complications of pro-
cedures to treat DFU). The causes of death were classiﬁed
into CVD-speciﬁc mortality and non-CVD mortality
according to the International Classiﬁcation of Diseases,
Ninth Edition. The direct cause of death or underlying
disease was considered only; diseases in the pathway to
death (secondary causes) were ignored in ascertaining
cause of death for analysis. Causes of death were deter-
mined by J.B. and M.G., and any disputes were resolved by
the senior author (R.H.).
Statistical analysis. Continuous variables are expressed
as mean 6 standard deviation; categorical variables are pre-
sented as percentages. Differences between groups were
assessed by a combination of c2 test and unpaired t-tests,for categorical and continuous data, respectively. To test
the association between DFU and all-cause mortality,
Kaplan-Meier curves were developed with 95% CIs and
standard errors. Patients lost to follow-up were censored
on the date of last known follow-up. Survivors were
censored at the end of follow-up when individual mortality
data were ascertained. Cox proportional hazards regression
was used to obtain the HRs and 95% CIs for all-cause
mortality. Potential confounding variables were selected
on the basis of established evidence demonstrating their
association with all-cause mortality. In the adjusted model
for all-cause mortality, we considered the following po-
tential confounders: demographics (age, gender), cardio-
vascular factors (hypertension, dyslipidemia, smoking history,
antihypertensive medication use, and history of CVD),
comorbidities (chronic kidney disease stage 3-5, chronic
obstructive pulmonary disease, history of neoplasm), diabetes-
speciﬁc variables (duration of diabetes, hemoglobin A1c,
insulinuse, anduseof oral antihyperglycemicmedication), and
incident revascularization or major amputation procedure.
Cardiovascular and nonvascular mortality estimates were
calculated from the cumulative incidence of competing risks
from baseline by the Fine and Gray method.8 The Cox
regression analysis, modiﬁed for competing risks for cardio-
vascular and nonvascular mortality, identiﬁed univariable and
multivariable associations with outcome for each group. Var-
iables considered in univariable analysis for cardiovascular
mortality included demographics (age, gender), history of
myocardial infarction, coronary revascularization, stroke,
PAD, congestive cardiac failure, smoking, hypertension, hy-
percholesterolemia, chronic kidney disease (stage, 3-5), or
antihypertensive use. Variables selected for multivariable
analysis were those demonstrating a signiﬁcant association
with each outcome measure at a P < .5 level in univariable
analysis. To avoid collinearity among variables with strong
associations (eg, hypertension, antihypertensive therapy, use
of renin-angiotensin blockade), we entered into the multi-
variable models the variable that had the strongest association
with all-cause or CVD mortality. We calculated that a sample
size of 800 patients would be more than sufﬁcient to detect
increased relative risks between 1.41 and 2.22 for CVD mor-
tality with 80% power,3 assuming a two-sided test and a sig-
niﬁcance level of .05. Furthermore, the authors were satisﬁed
that such differences would be clinically meaningful. Statistical
analyses were performed with SPSS version 22.0 (SPSS Inc,
Chicago, Ill) and R (cmprsk package; r-project.org).
RESULTS
A total of 869 patients were included in the study (436
in the DM group and 433 in the DFU group). Median
follow-up duration in the DFU group was 3.7 years (inter-
quartile range, 3.3-4.3 years) compared with 3.6 years
(interquartile range, 3.3-4.1 years) in the DM-only group.
Mean age was similar between the groups (Table I).
Compared with patients with DM only, those in the
DFU group were more frequently male with a greater prev-
alence of CVD, including ischemic heart disease, stroke,
and PAD (P < .01). Accordingly, patients with DFU
Table I. Baseline clinical characteristics
DM
(n ¼ 436)
DFU
(n ¼ 433)
P
value
Age, years 68.3 6 10.3 68.8 6 13.3 .58
Female 207 (47.5) 132 (30.5) <.001
Type 2 diabetes 409 (93.8) 413 (95.4) .18
Duration of diabetes, years 12.9 6 5.3 13.8 6 7.8 .10
Metformin 207 (47.5) 157 (36.3) .06
Insulin 298 (68.3) 320 (73.9) .58
Hemoglobin A1c, % 62.0 6 18.3 62.5 6 24.3 .74
IHD 217 (49.8) 267 (61.7) <.001
Coronary revascularization 49 (11.2) 49 (11.3) .97
Stroke 51 (11.7) 83 (19.2) .006
PAD 105 (24.1) 192 (44.3) <.001
CCF 248 (56.9) 251 (58.0) .75
COPD 103 (23.6) 111 (25.6) .49
Smoking history 134 (30.8) 216 (49.9) <.001
Hypertension 388 (89.0) 377 (87.1) .38
Hypercholesterolemia 394 (90.4) 370 (85.5) .03
CKD stage 3-5 195 (44.7) 241 (55.7) .002
Cancer 48 (11.0) 41 (9.5) .45
Antihypertensive 367 (84.2) 371 (85.7) .54
ACEi/ARB 329 (75.5) 301 (69.5) .05
Antiplatelet 178 (40.8) 269 (62.1) <.001
Warfarin 22 (5.0) 17 (3.9) .18
ACEi, Angiotensin-converting enzyme inhibitor; ARB, angiotensin recep-
tor blocker; CCF, congestive cardiac failure; CKD, chronic kidney disease;
COPD, chronic obstructive pulmonary disease; DFU, diabetic foot ulcera-
tion; DM, diabetes mellitus; IHD, ischemic heart disease; PAD, peripheral
arterial disease.
Fig 1. Kaplan-Meier estimate of survival functions for all-cause
mortality in diabetes mellitus (DM) vs diabetic foot ulceration
(DFU). The 95% conﬁdence intervals (CIs) are presented. All
standard errors <.02 (Supplementary Table I, online only).
Table II. Cause-speciﬁc mortality in diabetes mellitus
(DM) vs diabetic foot ulceration (DFU)
DM
(n ¼ 436)
DFU
(n ¼ 433)
All cause 28 117
Vascular
Ischemic heart disease 5 14
Stroke e 2
Other vascular disease e 6
Neoplastic
Lung cancer 1 e
Upper aerodigestive cancer 2 2
Other speciﬁed cancer 3 12
Other
Kidney disease (non-neoplastic) 3 13
Liver disease (non-neoplastic) 1 2
Respiratory disease 7 29
Urosepsis 1 7
Foot sepsis e 9
Hip fracture 1 4
Other speciﬁed disease e 6
Unknown 2 11
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although the prevalence of hypertension did not differ
signiﬁcantly. Patients with DFU were more frequently
receiving an antiplatelet agent.
The crude mortality rates among patients in the DFU
and DM groups were 27.0% (117 of 433) and 6.4% (28 of
436), respectively (unadjusted HR, 4.84; 95% CI, 3.18-
7.36; P < .001). Fig 1 shows the Kaplan-Meier curves for
all-cause mortality (all standard error values < .02;
Supplementary Table I, online only). The adjusted HR for
the association between DFU and all-cause mortality was
3.98 (95% CI, 2.55-6.21; P < .001). Patients with DFU
had an approximately threefold increased risk of CVD-
speciﬁc mortality after adjustment for the competing risk
of nonvascular death (adjusted HR, 2.53; 95% CI, 0.98-
6.49; P ¼ .054). Despite this, of the total number of deaths
in each group, the proportion attributable to cardiovascular
causes was similar between the groups (18% in the DM-only
group vs 19% in the DFU group; P ¼ .91) (Table II). As
shown in Table III and Fig 2, the 2-year risk of cardiovascu-
lar mortality in the DFU group was 3% compared with 1% in
the DM group. The corresponding risks for nonvascular
death were higher, at 15% and 3% for the DFU and DM
groups, respectively. Foot ulceration demonstrated a signif-
icant association with nonvascular death in considering car-
diovascular death as a competing risk (adjusted HR, 4.42;
95% CI, 2.57-6.61; P < .001). Variables considered in
univariable and multivariable analysis are presented in
Supplementary Tables II to IV (online only).A total of 24 patients (5.5%) in the DFU group under-
went a major amputation compared with a single patient
(0.2%) in the DM group (P < .001); however, major ampu-
tation during the follow-up period demonstrated no signiﬁ-
cant association with all-cause mortality in univariable or
multivariable analysis (Supplementary Table II, online
only). A revascularization procedure was performed in 69
patients (15.9%) in the DFU group (63 endovascular and
22 surgical bypass procedures) compared with four patients
(0.9%) in the DM group (three endovascular and one surgi-
cal bypass procedure) (P < .001). Whereas an endovascular
procedure was associated with all-cause mortality in univari-
able analysis (HR, 2.31; 95% CI, 1.45-3.68; P < .001), the
association did not remain signiﬁcant after adjustment for
potential confounders in multivariable analysis. An incident
Table III. Cumulative event rates for cardiovascular and
nonvascular death
Time from baseline, years
1 2 4
DM (n ¼ 436), %
Cardiovascular death 0.005 0.007 0.012
Nonvascular death 0.014 0.034 0.058
DFU (n ¼ 433), %
Cardiovascular death 0.018 0.030 0.056
Nonvascular death 0.074 0.148 0.224
DFU, Diabetic foot ulceration; DM, diabetes mellitus.
Fig 2. Cumulative incidence functions for nonvascular death (1)
and cardiovascular death (2) in patients with diabetes mellitus
(DM) vs diabetic foot ulceration (DFU).
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all-cause mortality. PAD demonstrated a signiﬁcant univari-
able association with eachmortality outcome (all-cause mor-
tality, cardiovascular mortality, and nonvascular mortality);
however, the associations were not signiﬁcant after adjust-
ment for potential confounders (Supplementary Tables II
to IV, online only). The association of DFU with all-cause
mortality remained signiﬁcant in multivariable analysis after
the exclusion of patients with PAD (adjusted HR, 4.54;
95% CI, 2.58-7.97; P < .001).
DISCUSSION
These ﬁndings from a secondary care clinic cohort of
patients with diabetes indicate that foot ulceration is associ-
ated with premature death from all causes. On average, a
person with diabetes who developed foot ulceration was
around 3 years younger at the time of death than a counter-
part with diabetes. Importantly, the association between
DFU and premature mortality observed in the present study
is additive to that associated with diabetes itself, for which
the reduction in life expectancy is about 6 years.1 In additionto an excess odds of overall mortality, our results show that
DFU is associated with a more than twofold increased risk of
premature death from cardiovascular causes.
Several mechanisms may explain the link between DFU
and increased overall mortality. First, DFU is associated
with increased duration of diabetes, longer exposure to
risk, and greater likelihood of multisystem disease. Second,
active ulceration has been shown to elicit numerous adverse
biologic responses, most notably chronic inﬂammation,
which has an established role in the development and pro-
gression of atherosclerosis. Given that the average time to
healing for a diabetic foot ulcer is between 3 and
6 months,9 and around 40% of patients who achieve heal-
ing of a foot ulcer will experience recurrence within
1 year,10 the inﬂammatory cascade associated with ulcera-
tion may exert adverse cardiovascular effects intermittently
during a prolonged period. In addition, consequences of
foot ulceration in the short term may include sepsis and
its sequelae (eg, multiorgan failure). Third, DFU is associ-
ated with microangiopathy and macroangiopathy. PAD is a
consistent independent predictor of CVD and all-cause
mortality and is present in around 50% (44% in this study)
of patients with DFU. Despite this, the association between
DFU and mortality remained signiﬁcant after exclusion of
patients with PAD. Indeed, the point estimate for the asso-
ciation between DFU and mortality was greater after the
exclusion of patients with PAD, which suggests that the
burden of disease and inﬂammatory sequelae of ulceration
may exert greater inﬂuences on mortality.
The present ﬁndings extend the results of smaller studies
that have examined the association between foot ulceration
and cause-speciﬁc mortality.11-18 In a meta-analysis of these
studies,3 cardiovascular death accounted for 44% of overall
deaths in both the diabetes group and the DFU group.
Whereas the proportion of CVD deaths reported in the pre-
sent study was consistent across the two groups, it was
considerably smaller (18%-19%) than in previous reports.
Differences in the study populations may account for this
discrepancy. In contrast to the present report, which studied
a secondary care clinic cohort, the aforementioned meta-
analysis included studies of population registries and primary
care and outpatient cohorts. Further, the majority of studies
included in the meta-analysis were based on data recorded
up to a decade before the present study. These data largely
predate contemporary guidelines on the management of
cardiovascular risk. Cardiovascular risk management in the
present study was optimized by secondary care physicians
in an interdisciplinary environment.
If active ulceration and its inﬂammatory sequelae
signiﬁcantly contribute to overall mortality, then effective
strategies to reduce deaths must rely, in part, on preventing
ulceration. Annual foot checks undertaken in primary care
in the United Kingdom as part of the Quality and Out-
comes Framework will identify individuals at high risk of
foot ulceration19; however, the effectiveness of these
screening programs and interventions in reducing both
the risk of foot ulceration and mortality is difﬁcult to
conﬁrm.20,21 Conversely, if ulceration is simply a surrogate
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ease, efforts to attenuate mortality must focus on an earlier
stage of the disease process.
Once ulceration has occurred, reports suggest that
pharmacologic management of cardiovascular risk can
improve survival.22 In a diabetic foot clinic population in
Scotland, the introduction of intensive cardiovascular risk
modiﬁcation incorporating cardiovascular risk screening
and administration of an antiplatelet agent, statin, and anti-
hypertensive, where indicated, resulted in a reduction in
5-year mortality from 48% to 27%.22 Mortality data from
the present study are comparable with ﬁndings from this
Edinburgh study following the introduction of intensive
cardiovascular risk modiﬁcation and conﬁrm the high mor-
tality in this patient group despite good preventive therapy.
Several limitations of our study should be considered.
We acknowledge that the data presented derive from a
cohort of outpatients, and the generalizability of our ﬁnd-
ings to differing populations cannot be assumed. We lacked
information on microvascular complications of diabetes,
including nephropathy, retinopathy, and neuropathy. It is
possible that microvascular disease, a key risk factor for
ulceration and mortality, may have been more prevalent in
the DFU group and may contribute signiﬁcantly to the
excess mortality observed. Despite adjustment for several
potential confounding variables, our results may be subject
to residual bias owing to unmeasured risk factors, including
information on the microvascular complications of diabetes.
CONCLUSIONS
DFU is associated with premature death from vascular
and nonvascular causes. These ﬁndings highlight the need
for a better understanding of the multisystem conse-
quences of DFU. Whether prevention of ulceration miti-
gates these risks remains to be established.
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Supplementary Table I (online only). Standard error
(SE) for Kaplan-Meier analysis of all-cause mortality
Time No. at risk No. of events Survival SE
37 869 1 0.999 0.00115
42 868 1 0.998 0.00163
52 867 1 0.997 0.00199
79 866 1 0.995 0.00230
80 865 1 0.994 0.00257
108 863 1 0.993 0.00281
110 862 1 0.992 0.00303
116 861 1 0.991 0.00324
125 860 1 0.990 0.00344
135 859 1 0.988 0.00362
136 858 1 0.987 0.00379
188 857 1 0.986 0.00396
190 856 1 0.985 0.00412
194 855 2 0.983 0.00442
201 853 1 0.982 0.00456
211 852 1 0.980 0.00470
215 851 1 0.979 0.00484
216 850 1 0.978 0.00497
221 849 1 0.977 0.00509
231 848 1 0.976 0.00521
234 847 1 0.975 0.00533
240 846 1 0.974 0.00545
249 845 2 0.971 0.00568
257 843 2 0.969 0.00589
266 841 1 0.968 0.00600
267 840 1 0.967 0.00610
268 839 1 0.965 0.00620
276 838 1 0.964 0.00630
281 837 1 0.963 0.00639
282 836 1 0.962 0.00649
286 835 2 0.960 0.00668
288 833 1 0.959 0.00677
289 832 1 0.957 0.00686
292 831 1 0.956 0.00694
297 830 2 0.954 0.00712
312 828 1 0.953 0.00720
316 827 1 0.952 0.00728
328 826 1 0.950 0.00736
333 825 1 0.949 0.00744
338 824 1 0.948 0.00752
341 823 1 0.947 0.00760
348 822 1 0.946 0.00768
361 821 1 0.945 0.00776
372 820 1 0.944 0.00783
373 819 1 0.942 0.00791
377 818 2 0.940 0.00805
379 816 2 0.938 0.00820
393 814 2 0.935 0.00834
402 812 1 0.934 0.00841
406 811 1 0.933 0.00847
410 810 3 0.930 0.00868
412 807 1 0.929 0.00874
413 806 1 0.927 0.00881
414 805 1 0.926 0.00887
423 804 1 0.925 0.00893
428 803 1 0.924 0.00900
434 802 1 0.923 0.00906
448 801 1 0.922 0.00912
450 800 1 0.921 0.00918
451 799 1 0.919 0.00924
463 798 1 0.918 0.00930
509 797 1 0.917 0.00936
515 796 1 0.916 0.00942
523 795 1 0.915 0.00948
524 794 1 0.914 0.00954
Supplementary Table I (online only). Continued.
Time No. at risk No. of events Survival SE
531 793 1 0.912 0.00959
541 792 2 0.910 0.00971
542 790 1 0.909 0.00976
548 789 1 0.908 0.00982
564 788 1 0.907 0.00987
565 787 1 0.906 0.00993
566 786 1 0.904 0.00998
574 785 1 0.903 0.01003
575 784 1 0.902 0.01009
593 783 1 0.901 0.01014
601 782 1 0.900 0.01019
623 781 1 0.899 0.01024
631 780 1 0.897 0.01030
635 779 1 0.896 0.01035
646 778 1 0.895 0.01040
651 777 1 0.894 0.01045
662 776 1 0.893 0.01050
692 775 1 0.892 0.01055
719 774 1 0.891 0.01060
777 773 1 0.889 0.01064
778 772 1 0.888 0.01069
808 771 1 0.887 0.01074
820 770 1 0.886 0.01079
840 769 2 0.884 0.01088
853 767 1 0.882 0.01093
864 766 1 0.881 0.01098
871 765 1 0.880 0.01102
878 764 1 0.879 0.01107
884 763 1 0.878 0.01111
886 762 2 0.876 0.01120
888 760 1 0.874 0.01125
901 759 1 0.873 0.01129
907 758 1 0.872 0.01133
910 757 1 0.871 0.01138
913 756 1 0.870 0.01142
932 755 1 0.869 0.01146
953 751 1 0.868 0.01151
956 750 1 0.866 0.01155
958 749 1 0.865 0.01159
964 748 1 0.864 0.01163
967 747 1 0.863 0.01168
968 746 1 0.862 0.01172
975 743 1 0.861 0.01176
991 736 1 0.858 0.01184
996 730 1 0.857 0.01188
1029 715 1 0.856 0.01193
1035 710 1 0.855 0.01197
1037 709 1 0.853 0.01202
1039 706 1 0.852 0.01206
1040 705 2 0.850 0.01215
1045 695 1 0.849 0.01219
1058 689 1 0.847 0.01223
1085 667 1 0.846 0.01228
1133 625 1 0.845 0.01234
1151 613 1 0.843 0.01239
1154 604 1 0.842 0.01245
1158 602 1 0.841 0.01251
1180 564 1 0.839 0.01257
1182 560 1 0.838 0.01264
1204 510 1 0.836 0.01272
1207 505 1 0.834 0.01280
1209 500 1 0.833 0.01289
1215 493 1 0.831 0.01297
1301 348 1 0.829 0.01315
1373 294 1 0.826 0.01341
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Supplementary Table II (online only). Independent associations with all-cause mortality in a multivariable Cox model
Parameter HR 95% CI P value HR 95% CI P value
DFU 4.84 3.18-7.36 <.001 3.98 2.55-6.21 <.001
Age, years 1.07 1.05-1.08 <.001 1.05 0.03-1.07 <.001
Female 0.89 0.63-1.25 .50
Type 2 diabetes 4.16 1.03-16.82 .05 1.19 0.28-4.98 .81
Duration of diabetes, years 1.00 0.99-1.00 .56
Metformin 1.12 0.80-1.56 .51
Insulin 0.76 0.54-1.08 .13 0.70 0.48-1.02 .06
Hemoglobin A1c, % 1.02 1.01-1.03 .001
Myocardial infarction 1.66 1.17-2.35 .005 1.28 0.87-1.90 .21
Coronary revascularization 0.58 0.31-1.11 .10 0.45 0.23-0.88 .02
Stroke 1.77 1.19-2.62 .005 1.05 0.69-1.60 .83
PAD 2.13 1.53-2.96 <.001 1.26 0.87-1.82 .22
CCF 1.34 0.95-1.89 .10 0.85 0.58-1.27 .43
COPD 2.72 1.95-3.79 <.001 2.23 1.54-3.22 <.001
Smoking history 1.67 1.20-2.32 .002 0.95 0.66-1.36 .78
Hypertension 1.26 0.73-2.19 .41 0.91 0.49-1.66 .75
Hypercholesterolemia 1.19 0.70-2.04 .52
CKD stage 3-5 2.34 1.58-3.45 <.001 1.94 1.27-2.96 .002
Cancer 2.40 1.58-3.65 <.001 2.14 1.40-3.28 <.001
ACEi/ARB 1.07 0.74-1.56 .71
Antiplatelet 1.73 1.23-2.43 .002 1.27 0.88-1.83 .21
Major amputation 1.52 0.67-3.44 .32 1.02 0.42-2.51 .96
Endovascular revascularization 2.31 1.45-3.68 <.001 0.78 0.46-1.33 .36
Open revascularization 1.33 0.55-3.26 .53
ACEi, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCF, congestive cardiac failure; CI, conﬁdence interval; CKD, chronic
kidney disease; COPD, chronic obstructive pulmonary disease; DFU, diabetic foot ulceration; HR, hazard ratio; IHD, ischemic heart disease; PAD, peripheral
arterial disease.
Supplementary Table III (online only). Independent associations with the cumulative incidence of cardiovascular
mortality in a Fine and Gray (proportional hazards) model after accounting for the competing risk of noncardiovascular
death
Parameter HR 95% CI P value HR 95% CI P value
DFU 4.58 1.74-12 .002 2.53 0.98-6.49 .05
Age, years 1.07 1.03-1.12 .001 1.06 1.02-1.10 .007
Female 2.29 0.92-5.69 .08 1.84 0.71-4.77 .21
Myocardial infarction 2.34 0.99-5.48 .05 0.98 0.37-2.59 .97
Coronary revascularization 1.02 0.31-3.37 .98
Stroke 2.38 1.04-5.45 .04 1.28 0.49-3.30 .62
PAD 2.47 1.16-5.26 .02 1.20 0.45-3.22 .71
CCF 4.41 1.53-12.7 .01 1.97 0.74-5.23 .17
Smoking history 2.51 1.14-5.53 .02 1.49 0.65-3.43 .35
Hypertension 1.11 0.34-3.66 .87
Hypercholesterolemia 1.73 0.41-7.27 .45 1.03 0.26-4.12 .97
CKD stage 3-5 17.90 2.44-132.00 .005 11.52 1.67-79.43 .01
ACEi/ARB 0.543 0.25-1.17 .12 0.42 0.19-0.94 .03
Antiplatelet 2.8 1.19-6.60 .02 2.43 1.06-5.58 .04
ACEi, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCF, congestive cardiac failure; CI, conﬁdence interval; CKD, chronic
kidney disease; COPD, chronic obstructive pulmonary disease; DFU, diabetic foot ulceration; HR, hazard ratio; IHD, ischemic heart disease; PAD, peripheral
arterial disease.
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Supplementary Table IV (online only). Independent associations with the cumulative incidence of noncardiovascular
mortality in a Fine and Gray (proportional hazards) model after accounting for the competing risk of cardiovascular death
Parameter HR 95% CI P value HR 95% CI P value
DFU 4.59 2.91-7.24 <.001 4.42 2.57-6.61 <.001
Age, years 1.06 1.04-1.08 <.001 1.04 1.02-1.06 <.001
Female 0.96 0.66-1.38 .81
Myocardial infarction 1.52 1.04-2.23 .03 1.16 0.75-1.78 .51
Coronary revascularization 0.48 0.22-1.02 .06 0.39 0.18-0.85 .02
Stroke 1.62 1.05-2.50 .03 0.84 0.51-1.38 .49
PAD 2.04 1.42-2.92 <.001 1.30 0.87-1.95 .20
CCF 1.08 0.75-1.56 .68
COPD 2.55 1.77-3.65 <.001 2.09 1.39-3.14 <.001
Smoking history 1.57 1.1-2.26 .01 0.90 0.62-1.31 .57
Hypertension 1.22 0.68-2.22 .51
Hypercholesterolemia 1.13 0.64-2.00 .68
CKD stage 3-5 1.79 1.20-2.68 .005 1.31 0.86-1.99 .21
Cancer 3.12 2.04-4.77 <.001 2.84 1.80-4.46 <.001
ACEi/ARB 1.3 0.85-1.99 .23 1.14 0.73-1.77 .56
Antiplatelet 1.54 1.07-2.23 .02 0.99 0.67-1.47 .97
ACEi, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCF, congestive cardiac failure; CI, conﬁdence interval; CKD, chronic
kidney disease; COPD, chronic obstructive pulmonary disease; DFU, diabetic foot ulceration; HR, hazard ratio; IHD, ischemic heart disease; PAD, peripheral
arterial disease.
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